



(51) International Patent Classification:
C12N 15/113 (2010.01) A61K 9/51 (2006.01)

(21) International Application Number:
PCT/US2025/010228

(22) International Filing Date:
03 January 2025 (03.01.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/617,867 05 January 2024 (05.01.2024) US

(71) Applicant: **ARBOR BIOTECHNOLOGIES, INC.**
[US/US]; 20 Acorn Park Drive, Suite 500, Cambridge,
Massachusetts 02140 (US).

(72) Inventors: **DITOMMASO, Tia**; c/o Arbor Biotechnolo-
gies, Inc., 20 Acorn Park Drive, Suite 500, Cambridge,
Massachusetts 02140 (US). **KUEFNER, Michael**; c/o Ar-
bor Biotechnologies, Inc., 20 Acorn Park Drive, Suite 500,
Cambridge, Massachusetts 02140 (US). **GARRITY, An-
thony**; c/o Arbor Biotechnologies, Inc., 20 Acorn Park Drive,

ve, Suite 500, Cambridge, Massachusetts 02140 (US). **LIN,
Paulo Jia Ching**; 6190 Agronomy Rd., Suite #405, Van-
couver, British Columbia V6T 1Z3 (CA). **TAM, Ying K.**;
6190 Agronomy Rd., Suite #405, Vancouver, British Col-
umbia V6T 1Z3 (CA).


(74) Agent: **CHEN, Yahua**; c/o Mintz Levin, One Financial
Center, Boston, Massachusetts 02111 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

(54) Title: METHODS FOR TREATING PRIMARY HYPEROXALURIA VIA GENETIC EDITING OF HYDROXYACID OXI-
DASE 1

FIG. 1



(57) Abstract: A composition for genetic editing of a hydroxyacid oxidase 1 (HAO1) gene, comprising: (a) a messenger RNA (mRNA) encoding a Cas12i2 polypeptide, (b) a guide RNA (gRNA) targeting the HAO1 gene; and (c) lipid excipients, which optionally form lipid nanoparticles. Also provided herein are methods for genetic modification of the HAO1 gene in host cells with the composition provided herein.

[Continued on next page]

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*